- Home
- NKX vs PHAR Comparison
NKX vs PHAR Comparison
Compare NKX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKX
- PHAR
- Stock Information
- Founded
- NKX 2002
- PHAR 1988
- Country
- NKX United States
- PHAR Netherlands
- Employees
- NKX N/A
- PHAR N/A
- Industry
- NKX Finance/Investors Services
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- NKX Finance
- PHAR Health Care
- Exchange
- NKX Nasdaq
- PHAR Nasdaq
- Market Cap
- NKX 599.7M
- PHAR 627.5M
- IPO Year
- NKX N/A
- PHAR N/A
- Fundamental
- Price
- NKX $12.65
- PHAR $9.98
- Analyst Decision
- NKX
- PHAR Strong Buy
- Analyst Count
- NKX 0
- PHAR 3
- Target Price
- NKX N/A
- PHAR $27.00
- AVG Volume (30 Days)
- NKX 109.3K
- PHAR 5.6K
- Earning Date
- NKX 01-01-0001
- PHAR 03-13-2025
- Dividend Yield
- NKX 4.37%
- PHAR N/A
- EPS Growth
- NKX N/A
- PHAR N/A
- EPS
- NKX N/A
- PHAR N/A
- Revenue
- NKX N/A
- PHAR $285,745,000.00
- Revenue This Year
- NKX N/A
- PHAR $20.08
- Revenue Next Year
- NKX N/A
- PHAR $9.22
- P/E Ratio
- NKX N/A
- PHAR N/A
- Revenue Growth
- NKX N/A
- PHAR 30.64
- 52 Week Low
- NKX $9.78
- PHAR $6.65
- 52 Week High
- NKX $12.00
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- NKX 47.16
- PHAR 56.13
- Support Level
- NKX $12.42
- PHAR $9.37
- Resistance Level
- NKX $12.92
- PHAR $10.15
- Average True Range (ATR)
- NKX 0.24
- PHAR 0.50
- MACD
- NKX 0.02
- PHAR -0.09
- Stochastic Oscillator
- NKX 57.14
- PHAR 57.53
About NKX Nuveen California AMT-Free Quality Municipal Income Fund
Nuveen California AMT-Free Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objectives are to provide current income exempt from regular federal and California income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.